Health indices were boosted by an array of positive clinical trial news to start the holiday-shortened week Tuesday.
InterMune (ITMN) gained after announcing the Food and Drug Administration approved its amended clinical trial authorization (CTA) for ITMN-191, an orally available hepatitis C virus protease inhibitor that it's developing with Roche.
InterMune said in May that it would amend the CTA to take into consideration new information from a phase Ia study that was completed that month. The company expects to begin the phase Ib study this month and to announce initial top-line results in the first quarter of 2008.
The stock rose $2.06, or 10.4%, to $21.83, helping to support the Nasdaq biotechnology index, which added 16.4, or 2.4%, to 830.1.Also winning Tuesday, NeurogesX (NGSX) announced